Laninamivir is an influenza antiviral, known as a neuraminidase inhibitor (LANI) and a treatment for influenza.
The contract is designed to provide US based manufacturing and clinical data to support a new drug application (NDA) for Laninamivir, to the US Food and Drug Administration.
Biota CEO Peter Cook said the BARDA contract will be a major contributor to a timely introduction of the product and will create the opportunity to significantly develop Biota’s business in the US.